Director of Microbiology (Consultant)
Allecra Therapeutics SAS, Canada
Adam C. Belley, Ph.D. is the Director of Microbiology (consultant) at Allecra Therapeutics SAS supporting the development and regulatory submissions of the investigational drug combination EXBLIFEP® (cefepime-enmetazobactam), which has completed a phase 3 clinical trial for complicated urinary tract infections caused by resistant Gram-negative pathogens. At The Medicines Company, he successfully contributed to the microbiological and preclinical development of the lipoglycopeptide antibiotic Orbactiv® (oritavancin, approved 2014). His career began at Phagetech, a biotech company using bacteriophage-inspired biology to discover new small-molecule antibacterial agents. Adam has a Ph.D. from the Institute of Parasitology of McGill University, Canada.